<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hims-Hers-Health-Inc-US4330001060">Hims &amp; Hers Health Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260602926942/en/Hims-Hers-Completes-Acquisition-of-Eucalyptus-Expanding-Access-to-Comprehensive-Clinically-Backed-Weight-Management-Care-in-Germany/">Hims &amp; Hers Completes Acquisition of Eucalyptus, Expanding Access to Comprehensive, Clinically-Backed Weight Management Care in Germany</a>
    </div>

      <div class="me-0 me-md-5">
        BERLIN--(BUSINESS WIRE)--Hims &amp; Hers Health, Inc. has completed its acquisition of Eucalyptus, the parent company of Juniper, advancing its position as the world&#39;s largest consumer health platform. In Germany, the closing strengthens Juniper&#39;s comprehensive, clinically rigorous, weight management offering with the technology, data, and infrastructure of Hims &amp; Hers behind it. Since launching in...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hims-Hers-Health-Inc-US4330001060">Hims &amp; Hers Health Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260528501192/en/Hims-Hers-Expands-Benefits-for-Active-Subscribers-With-Eight-New-Health-and-Wellness-Partners/">Hims &amp; Hers Expands Benefits for Active Subscribers With Eight New Health and Wellness Partners</a>
    </div>

      <div class="me-0 me-md-5">
        SAN FRANCISCO--(BUSINESS WIRE)--Hims &amp; Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the expansion of Hims &amp; Hers Benefits, adding eight new partners to the Hims &amp; Hers exclusive program. Joining founding partners Prenuvo and Eight Sleep are Natural Cycles, MyFitnessPal, Ladder, PVOLVE Studios, HelloFresh, Factor, Flo Health, Dexcom, and iFIT - a care...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-danger bg-red-100">
          Negative
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hims-Hers-Health-Inc-US4330001060">Hims &amp; Hers Health Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Proactive Investors</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.proactiveinvestors.com/companies/news/1092908?SNAPI">Hims &amp; Hers faces steep climb to hit 2026 guidance as Wegovy churn risk looms, says BofA</a>
    </div>

      <div class="me-0 me-md-5">
        Hims &amp; Hers Health (NYSE: HIMS) faces a demanding customer acquisition challenge to hit its 2026 revenue guidance amid rising churn risks tied to its oral Wegovy subscription model, Bank of America said. Analysts estimate HIMS would need to add approximately 225,000 new oral Wegovy subscribers per quarter from the second through fourth quarters of 2026 to reach the midpoint of its full-year sal...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hims-Hers-Health-Inc-US4330001060">Hims &amp; Hers Health Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/legal/litigation/hims-offers-apotexs-generic-semaglutide-canada-after-novo-patent-expiry-2026-05-21/">Hims offers Apotex&#39;s generic semaglutide in Canada after Novo patent expiry</a>
    </div>

      <div class="me-0 me-md-5">
        Hims &amp; Hers Health said on Thursday it is now offering Canadians with type 2 diabetes a ​generic version of semaglutide, the active ingredient in ‌Novo Nordisk&#39;s blockbuster drug Ozempic, through its platform.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hims-Hers-Health-Inc-US4330001060">Hims &amp; Hers Health Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260520249611/en/Hims-Hers-Expands-GLP-1-Offering-in-Canada-with-Generic-Semaglutide/">Hims &amp; Hers Expands GLP-1 Offering in Canada with Generic Semaglutide</a>
    </div>

      <div class="me-0 me-md-5">
        SAN FRANCISCO--(BUSINESS WIRE)--Hims &amp; Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform in Canada. This is Hims &amp; Hers&#39; first international generic GLP-1 offering, demonstrating the company&#39;s ability to meet the unique needs of each global market it serves while continuing its international exp...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hims-Hers-Health-Inc-US4330001060">Hims &amp; Hers Health Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260520762631/en/Hims-Hers-Brings-First-Time-Access-to-Generic-Semaglutide-to-Canada/">Hims &amp; Hers Brings First-Time Access to Generic Semaglutide to Canada</a>
    </div>

      <div class="me-0 me-md-5">
        TORONTO--(BUSINESS WIRE)--Hims &amp; Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform for eligible customers in Canada. This makes affordable GLP-1 treatment accessible to Canadians for whom cost has long been a barrier to treatment. For eligible customers, personalised treatment plans are availabl...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hims-Hers-Health-Inc-US4330001060">Hims &amp; Hers Health Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260518180060/en/Hims-Hers-Health-Inc.-Prices-Upsized-350-Million-Convertible-Senior-Notes-Offering-to-Support-International-Expansion-and-Accelerate-AI-Driven-Platform-Investment/">Hims &amp; Hers Health, Inc. Prices Upsized $350 Million Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment</a>
    </div>

      <div class="me-0 me-md-5">
        SAN FRANCISCO--(BUSINESS WIRE)--Hims &amp; Hers Health, Inc. (“Hims &amp; Hers” or the “Company”, NYSE: HIMS) today announced the pricing of its offering of $350 million aggregate principal amount of 0.00% convertible senior notes due 2032 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as am...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hims-Hers-Health-Inc-US4330001060">Hims &amp; Hers Health Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260517417885/en/Hims-Hers-Health-Inc.-Announces-Proposed-Convertible-Senior-Notes-Offering-to-Support-International-Expansion-and-Accelerate-AI-Driven-Platform-Investment/">Hims &amp; Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment</a>
    </div>

      <div class="me-0 me-md-5">
        SAN FRANCISCO--(BUSINESS WIRE)--Hims &amp; Hers Health, Inc. (“Hims &amp; Hers” or the “Company”, NYSE: HIMS) today announced its intention to offer, subject to market and other conditions, $300 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Se...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/Hims-Hers-Health-Inc-US4330001060/load_more?page=7">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>